Внутривенное введение пантопразола (Австрийское многоцентровое исследование)

1. Metz DC. Potential uses of intravenous proton pomp inhibitors to
control gastric acid secretion. Digestion 2000; 62: 73–81.
2. Steinijans VW, Hober R, Hartmann M et al. Lack of pantoprazol drug
interactions in man: an updated review. J. Clin Pharmacol Ther 1996;
51: 243–62.
3. Adamek RJ, Szymanski C, Pfaffenbech B et al. Short-term triple therapy
with pantoprazol, clarithromycin and metronidazole for the healing
of Helicobacter pylori infection. Dtsch Med Wochenschr 1995: 120:
35860.
4. Pilotto A, Leandro G, Franceschi M et al. Rapid improvement of symptomatology
with pantoprazol, amoxycillin and metronidazole in Helicobacter
pylori-positive duodenal ulcer patients. Hepatogastroenterology
1999; 46: 245–51.
5. Frevel M, Daake H, Janisch HD et al. Eradication of Helicobacter
pylori with pantoprazole and two antibiotics: a comparison of two
short-term regimens. Aliment Pharmacol Ther 2000; 14: 1151–7.
6. Wurzer H, Schtze K, Bethke T et al. Efficacy and sately of pantoprazole
in patients with gastroehageal reflux disease using intravenous-oral
regimen. Hepatogastroenterology 1999; 46: 1809–15.
7. Plein K, Schneider A, Fischer R et al. Wirksamkeit und Sicherheit einer
sequentiellen intravensen und oralen Behandlung mit Pantoprazol bei
Rfluxsophagitis. Leber Magen Darm 2000; 30: 164–8.
8. Kyzekova J, Mour J. The effect of eradication therapy on histological
changes in the gastric mucosa in patients woth non-ulcer dyspepsia
and Helicobacter pylori infection. Prospective randomized intervention
study. Hepatogastroenterology 1999; 46: 2048–56.
9. Pilotto A, Di Mario F, Franceschi M et al. Pantoprazole versus oneweek
Helicobacter pylori eradication therapy for the prevention of
acute NSID-related gastroduodenal damage in eldery subjects. Aliment
Pharmacol Ther 2000; 14: 1077–82.
10. Lew EA, Pisegna JR, Starr JA et al. Interavenous pantoprazole rapidly
controls gastric acid hypersecretion in patients with Zollinger-Ellison
syndrome. Gastroenterology 2000; 118: 696–704.
11. Bardhan KD, Cherian P, Bishop AE et al. Pantoprazole therapy in
the long-term management of sevire acid peptic disease: clinical efficacy,
safety, serum gastrin, gastric hostology, and endocrine cell studiens.
Am J Gastroenterol 2001; 96: 1767–76.
12. Barkum AN, Cockeram AW, Plourde V et al. Review article: acid suppression
in non-variceal acute upper gastrointerstinal bleeding.
Alimetn Pharmacol Ther 1999; 13: 1565084.
13. Selby NM, Kubba AK, Hawkey CJ. Acid suppression in peptic ulcer
haemorrhage: a meta-analysis. Aliment Pharmacol Ther 2000; 14:
1119–26.
14. Hartmann M, Ehrlich A, Fuder H et al. Equipotent ingibition of gastric
acid secretion by equal doses of oral or intrevenosus pantoprazole.
Aliment Pharmacol Ther 1998; 12: 1027–32.
15. Pisegna JR. Switching between intravenous and oral pantoprazole. J
clin Gastroenterol 2001; 32: 27–32.
16. Bosseckert H, Sander P, Braun W. Tolerability and efficacy of intravenous
anministration of pantoprazole in routine clinical practice. Clin
Drug Invest 2000; 19: 103–9.
17. Brunner G, Chang J. Intravenous therapy with high doses of ranitidine
and omeprazole in critically ill patients with bleeding peptic ulcerations
of the upper gastrointerstinal tract: an poen randomazied controlled
trial. Digestion 1990; 54: 217–25.
18. Sheu BS, Chi CH, Huang CC et al. Impact of intravenous pmeprazole
of helicobacter pylori eradication by triple therapy in patients with peptic
ulcer bleeding. Aliment Pharmacol Ther 2002; 16: 137–43.
19. Bardhan KD. Pantoprazole: a new proton pump inhibitor in the
management of upper gastrointerstinal disease. Drugs of Today 1999;
35: 773–808.